BACKGROUND: Studies in anti-neutrophil cytoplasm antibody (ANCA)-associated @entity1333 (AAV) have revealed promising biomarkers. The aim of our study was to validate the most encouraging markers of @entity2883 with @entity2883 and @entity6129 identified by literature search and to create biomarker panels. METHODS: A systematic literature review was performed and we identified 161 marker molecules that were ranked by their quantitative differential expression between active and inactive disease. Enzyme-linked immunosorbent assays were used to validate the results in a cross-sectional cohort of @entity1 with renal involvement. Active @entity1333 as assessed by the Birmingham @entity1333 Score version 3 (BVAS v3) was defined as BVAS v3 >= 1 and inactive disease as BVAS v3 = 0. Statistical analysis was performed with SPSS version 21 and the Salford Predictive Modeler 7.0 was used to generate a predictive biomarker panel. RESULTS: The review indicated abundant expression of sC5bC9, @entity4417 , @entity2242 and @entity2842 in urine, whereas granulocyte macrophage colony-stimulating factor, C-reactive protein (CRP), soluble fms-like @entity4149 kinase-1, @entity4155 ( @entity4155 ), @entity2242 , hyaluronan, @entity4417 and @entity10454 ( @entity10454 ) were identified to be highly diverse in active and inactive disease in blood samples. Our cross-sectional analysis revealed significant up-regulation of CRP, @entity2242 , @entity4417 , @entity10454 in blood and @entity2242 and @entity2842 in urine samples during active AAV (all P < 0.05). Creation of a biomarker panel comprising CRP and urinary @entity2842 yielded a sensitivity and specificity of 76% (area under the curve 0.89). CONCLUSIONS: We identified promising biomarkers in a literature-based review that were in part corroborated as has been shown for CRP, @entity4417 , @entity2242 , @entity10454 in blood and @entity2842 and @entity2242 in urine samples. Moreover, we propose a biomarker panel comprising CRP and urinary @entity2842 in @entity1 with AAV and renal involvement. Further investigations to confirm our preliminary results are clearly warranted, including the reliability to predict disease relapses.

Evaluation and validation of biomarkers in @entity2883 with XXXX and @entity6129 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis', 'vasculitis'] @entity10454 :: ('10068', 'Gene') :: ['IL-18BP', 'interleukin-18 binding protein'] @entity4417 :: ('718', 'Gene') :: ['C3a'] @entity6129 :: ('MESH:D055953', 'Disease') :: ['microscopic polyangiitis'] @entity2242 :: ('728', 'Gene') :: ['C5a'] @entity2842 :: ('6347', 'Gene') :: ['monocyte chemotactic protein (MCP)-1', 'MCP-1'] @entity4155 :: ('3605', 'Gene') :: ['IL-17A', 'interleukin-17A'] @entity2883 :: ('MESH:D014890', 'Disease') :: ['polyangiitis', 'granulomatosis'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity2883 :: (MESH:D014890,Disease) :: ['polyangiitis']
